Literature DB >> 16343048

Acute pancreatitis: proteinase-activated receptor-2 as Dr. Jekyll and Mr. Hyde.

R Matej1, D Housa, T Olejár.   

Abstract

"Proteinase-activated" receptor-2 (PAR-2) is a G protein-coupled transmembrane receptor with seven transmembrane domains activated by trypsin. It has been shown in the pancreatic tissue that PAR-2 is involved in duct/acinary cells secretion, arterial tonus regulation and capillary liquid content turnover under physiological conditions. These above mentioned structures play an important role during the development of acute pancreatitis and are profoundly influenced by a high concentration of trypsin enzyme after its secretion into the interstitial tissue from the basolateral aspect of acinar cells. Among the other factors, it is the increase of interstitial trypsin concentration followed rapidly by PAR-2 action on pancreatic vascular smooth muscle cells that initiates ischemic changes in pancreatic parenchyma and that finally leads to necrosis of the pancreas. Consequent reperfusion perpetuates changes leading to the acute pancreatitis development. On the contrary, PAR-2 action on both exocrine and duct structures seems to play locally a protective role during acute pancreatitis development. Moreover, PAR-2 action is not confined to the pancreas but it contributes to the systemic vascular endothelium and immune cell activation that triggers the systemic inflammatory response syndrome (SIRS) contributing to an early high mortality rate in severe disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16343048     DOI: 10.33549/physiolres.930798

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  4 in total

Review 1.  Recent insights into the cellular mechanisms of acute pancreatitis.

Authors:  Laura I Cosen-Binker; Herbert Y Gaisano
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

Review 2.  Gastrointestinal roles for proteinase-activated receptors in health and disease.

Authors:  A Kawabata; M Matsunami; F Sekiguchi
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

3.  Stability of 3-bromotyrosine in serum and serum 3-bromotyrosine concentrations in dogs with gastrointestinal diseases.

Authors:  Panpicha Sattasathuchana; Niels Grützner; Rosana Lopes; Blake C Guard; Jan S Suchodolski; Jörg M Steiner
Journal:  BMC Vet Res       Date:  2015-01-17       Impact factor: 2.741

4.  Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial.

Authors:  Morihisa Hirota; Tooru Shimosegawa; Katsuya Kitamura; Kazunori Takeda; Yoshifumi Takeyama; Toshihiko Mayumi; Tetsuhide Ito; Mamoru Takenaka; Eisuke Iwasaki; Hirotaka Sawano; Etsuji Ishida; Shin Miura; Atsushi Masamune; Yousuke Nakai; Akira Mitoro; Hiroyuki Maguchi; Kenji Kimura; Tsuyoshi Sanuki; Tetsuya Ito; Hiroki Haradome; Kazuto Kozaka; Toshifumi Gabata; Keisho Kataoka; Masahiko Hirota; Shuji Isaji; Ryoji Nakamura; Koki Yamagiwa; Chie Kayaba; Koji Ikeda
Journal:  J Gastroenterol       Date:  2019-11-22       Impact factor: 7.527

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.